Aetna modified CPB 0241 covering extracorporeal photochemotherapy (photopheresis) under CPT 36522, effective September 26, 2025. Here's what billing teams need to do.
Aetna, a CVS Health company, updated its extracorporeal photopheresis coverage policy under CPB 0241 Aetna system on September 26, 2025. The policy governs medical necessity criteria for CPT 36522 (photopheresis; extracorporeal) across five specific indications — from cutaneous T-cell lymphoma to refractory graft-versus-host disease. If your facility or practice bills photopheresis for transplant rejection, GVHD, or CTCL patients with Aetna coverage, this update deserves your attention before claims go out.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Extracorporeal Photochemotherapy (Photopheresis) |
| Policy Code | CPB 0241 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High — narrow criteria with multi-drug refractoriness requirements |
| Specialties Affected | Hematology/Oncology, Transplant Medicine, Dermatology, Pulmonology |
| Key Action | Audit documentation for CPT 36522 claims to confirm all refractory treatment criteria are captured before billing |
Aetna Photopheresis Coverage Criteria and Medical Necessity Requirements 2025
The Aetna photopheresis coverage policy under CPB 0241 covers CPT 36522 for five indications. Each one carries specific clinical thresholds. Meet them or expect a claim denial.
Indication 1: Cutaneous T-Cell Lymphoma (CTCL)
Aetna covers photopheresis for erythrodermic variants of CTCL — specifically mycosis fungoides and Sézary syndrome. The ICD-10 codes that support this include C84.0 through C84.9 (mycosis fungoides variants) and C84.10 through C84.19 (Sézary disease), plus C84.A0–C84.A9 (cutaneous T-cell lymphoma, unspecified). This is the broadest and most straightforward medical necessity pathway in the policy.
Indication 2: Acute Cardiac Allograft Rejection
Coverage requires the rejection to be refractory to standard immunosuppressive therapy. Specifically, the patient must be resistant or dependent on high-dose steroids AND refractory to at least two of the following (unless contraindicated): azathioprine, cyclosporine, methotrexate, and/or polyclonal or monoclonal antilymphocyte agents such as ALG or ATG. Document every failed agent in the chart. Aetna will look for this.
Indication 3: Lung Transplant Rejection (Bronchiolitis Obliterans)
The criteria mirror cardiac rejection — high-dose steroid resistance or dependence, plus failure of at least two of azathioprine, cyclosporine, tacrolimus, ALG, or ATG. There's a second pathway here: coverage is also available when there is a rapid decline in lung function, even without full multi-drug failure. That's a clinically significant carve-out. Make sure your pulmonologist documents lung function trajectory in the record, not just medication history.
Indication 4: Other Solid Organ Transplant Rejection
This is the narrowest pathway. Aetna covers photopheresis as a "last resort" only — when rejection is refractory to standard immunosuppressive therapy. The "last resort" language matters. Your documentation needs to show the full treatment history and why conventional options are exhausted.
Indication 5: Graft-Versus-Host Disease (GVHD)
Coverage applies to GVHD following allogeneic bone marrow or stem cell transplant when the disease is refractory to standard immunosuppressive therapy. The relevant diagnosis codes are D89.810–D89.813. This indication ties directly to the bone marrow and stem cell procedure codes (CPT 38204–38240) that appear as related codes in the policy.
Across all five indications, the real billing risk is documentation gaps. Aetna's reimbursement for CPT 36522 hinges on proof that prior therapies failed. If your records don't clearly establish multi-drug refractoriness, you're billing into a denial. Prior authorization requirements should also be confirmed at the plan level — Aetna plan-level prior auth rules vary, and this policy doesn't override that.
Aetna Photopheresis Exclusions and Non-Covered Indications
The published CPB 0241 does not list an explicit "not covered" or "experimental" section in the summary data available for this update. However, by implication, photopheresis billed under CPT 36522 for any indication not listed above — including autoimmune conditions, pemphigus, rheumatoid arthritis, Crohn's disease, or other off-label uses — does not meet Aetna's medical necessity criteria under this policy.
The 516-code ICD-10 list attached to this policy includes a wide range of diagnoses beyond the five covered indications. Codes like D59.0–D59.19 (acquired autoimmune hemolytic anemia), D69.0 (allergic purpura), D69.3 (immune thrombocytopenic purpura), and E05.0–E05.1 (thyrotoxicosis) appear in the policy's code table but are not among the five covered indications. Their presence in the code list does not mean photopheresis is covered for those diagnoses. If you're billing CPT 36522 with one of those ICD-10 codes, you need a defensible medical necessity argument — or you should expect a denial.
Talk to your compliance officer if your patient mix includes off-label photopheresis. The gap between what's in the code table and what's in the covered indications is a known audit risk.
Coverage Indications at a Glance
| Indication | Coverage Status | Key CPT Code | Medical Necessity Threshold |
|---|---|---|---|
| Erythrodermic CTCL (mycosis fungoides, Sézary syndrome) | Covered | 36522 | Erythrodermic variant confirmed |
| Acute cardiac allograft rejection | Covered | 36522 | Refractory to steroids + failure of ≥2 agents (azathioprine, cyclosporine, MTX, ALG/ATG) |
| Lung transplant rejection (bronchiolitis obliterans) | Covered | 36522 | Refractory to steroids + failure of ≥2 agents OR rapid lung function decline |
| Other solid organ transplant rejection | Covered (last resort) | 36522 | Refractory to all standard immunosuppressive therapy |
| GVHD (allogeneic BMT/SCT) | Covered | 36522 | Refractory to standard immunosuppressive therapy |
| Off-label indications (autoimmune, inflammatory, etc.) | Not covered under CPB 0241 | 36522 | Not addressed in policy; high denial risk |
Aetna Photopheresis Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit your open CPT 36522 claims before September 26, 2025. The effective date is the cutoff. Any claims for photopheresis billing that haven't been adjudicated should be reviewed against the five covered indications. If documentation is thin, pull the chart and add clinical notes now. |
| 2 | Build a documentation checklist for each covered indication. For transplant rejection cases, that checklist must include the names and doses of failed immunosuppressive agents, the duration of treatment, and the clinical response (or lack of it). For lung transplant cases, add pulmonary function test results showing rate of decline. For GVHD, confirm the transplant was allogeneic — autologous GVHD is not covered. |
| 3 | Verify prior authorization requirements at the plan level. This coverage policy establishes medical necessity criteria, but it doesn't tell you which Aetna plans require prior auth for CPT 36522. Call the plan or check the plan's portal before scheduling photopheresis sessions. A missing prior authorization is a denial that documentation can't fix retroactively. |
| 4 | Don't rely on the ICD-10 code list alone to confirm coverage. The 516 ICD-10 codes in this policy's code table include diagnoses that fall outside the five covered indications. Cross-reference the patient's diagnosis against the indication criteria — not just the code table. An ICD-10 match is not an automatic green light. |
| 5 | Flag GVHD cases for supporting procedure codes. If you're billing CPT 36522 for GVHD following a stem cell or bone marrow transplant, the related CPT codes in this policy (38204–38240) may need to appear in the patient's claim history. Make sure those transplant procedure codes are properly documented in prior encounters. This matters when Aetna reviews the clinical record for medical necessity. |
| 6 | Update your charge capture templates to include the refractoriness criteria. The most common denial pattern for photopheresis is missing documentation of prior treatment failure. Add structured fields or smart text templates that require the treating physician to document each failed agent before submitting CPT 36522. This is a workflow fix, not just a documentation reminder. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Photopheresis Under CPB 0241
Covered CPT Code (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 36522 | CPT | Photopheresis; extracorporeal |
Key ICD-10-CM Diagnosis Codes
The full policy includes 516 ICD-10-CM codes. Below are the primary diagnosis codes directly tied to the five covered indications.
| Code | Description |
|---|---|
| C84.0–C84.9 | Mycosis fungoides (multiple site-specific codes) |
| C84.10–C84.19 | Sézary's disease (multiple site-specific codes) |
| C84.A0–C84.A9 | Cutaneous T-cell lymphoma, unspecified |
| D89.810 | Acute graft-versus-host disease |
| D89.811 | Chronic graft-versus-host disease |
| D89.812 | Acute on chronic graft-versus-host disease |
| D89.813 | Graft-versus-host disease, unspecified |
Additional ICD-10 codes in the policy's 516-code table include D51.0, D59.0–D59.9, D69.0, D69.3, D76.3, E05.0–E05.1, and hundreds more. Their presence in the code table does not establish coverage for photopheresis under those diagnoses. Use them only when they accurately reflect the covered indication being treated.
Get the Full Picture for CPT 36522
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.